Abstract:Abstract Background Intensive evidence has highlighted the effect of aberrant alternative splicing (AS) events on cancer progression when triggered by dysregulation of the SR protein family. Nonetheless, the underlying mechanism in breast cancer (BRCA) remains elusive. Here we sought to explore the molecular function of SRSF1 and identify the key AS events regulated by SRSF1 in BRCA. Methods We conducted a comprehensive analysis of the expression and clinical correlation of SRSF1 in BRCA based on the TCGA dataset, Metabric database and clinical tissue samples. Functional analysis of SRSF1 in BRCA was conducted in vitro and in vivo. SRSF1-mediated AS events and their binding motifs were identified by RNA-seq, RNA immunoprecipitation-PCR (RIP-PCR) and in vivo crosslinking followed by immunoprecipitation (CLIP), which was further validated by the minigene reporter assay. PTPMT1 exon 3 (E3) AS was identified to partially mediate the oncogenic role of SRSF1 by the P-AKT/C-MYC axis. Finally, the expression and clinical significance of these AS events were validated in clinical samples and using the TCGA database. Results SRSF1 expression was consistently upregulated in BRCA samples, positively associated with tumor grade and the Ki-67 index, and correlated with poor prognosis in a hormone receptor-positive (HR+) cohort, which facilitated proliferation, cell migration and inhibited apoptosis in vitro and in vivo. We identified SRSF1-mediated AS events and discovered the SRSF1 binding motif in the regulation of splice switching of PTPMT1. Furthermore, PTPMT1 splice switching was regulated by SRSF1 by binding directly to its motif in E3 which partially mediated the oncogenic role of SRSF1 by the AKT/C-MYC axis. Additionally, PTPMT1 splice switching was validated in tissue samples of BRCA patients and using the TCGA database. The high-risk group, identified by AS of PTPMT1 and expression of SRSF1, possessed poorer prognosis in the stage I/II TCGA BRCA cohort. Conclusions SRSF1 exerts oncogenic roles in BRCA partially by regulating the AS of PTPMT1, which could be a therapeutic target candidate in BRCA and a prognostic factor in HR+ BRCA patient.

Opposing USP19 Splice Variants in TGF-β Signaling and TGF-β-induced Epithelial–mesenchymal Transition of Breast Cancer Cells

USP39 Promotes Hepatocellular Carcinogenesis Through Regulating Alternative Splicing in Cooperation with SRSF6/HNRNPC

A Regulatory Network Analysis of the Importance of USP15 in Breast Cancer Metastasis and Prognosis

USP18 Promotes Breast Cancer Growth by Upregulating EGFR and Activating the AKT/Skp2 Pathway

The deubiquitinase USP9X promotes tumor cell survival and confers chemoresistance through YAP1 stabilization.

The link between aberrant splicing and B cell infiltration in breast cancer hormone therapy

USP2 Promotes Progression in Triple Negative Breast Cancer

Usp17 Suppresses Tumorigenesis And Tumor Growth Through Deubiquitinating Aep

Splicing Factor USP39 Promotes Ovarian Cancer Malignancy Through Maintaining Efficient Splicing of Oncogenic HMGA2

USP39 promotes tumorigenesis by stabilizing and deubiquitinating SP1 protein in hepatocellular carcinoma

Deubiquitinating Enzyme USP9X Regulates Metastasis and Chemoresistance in Triple-Negative Breast Cancer by Stabilizing Snail1.

Direct Regulation of Alternative Splicing by SMAD3 Through PCBP1 is Essential to the Tumor-Promoting Role of TGF-β

USP8 promotes cancer progression and extracellular vesicle‐mediated CD8+ T cell exhaustion by deubiquitinating the TGF‐β receptor TβRII

Ubiquitin specific protease 21 upregulation in breast cancer promotes cell tumorigenic capability and is associated with the NOD-like receptor signaling pathway

Splicing factor SRSF1 promotes breast cancer progression via oncogenic splice switching of PTPMT1

USP22 Contributes to Chemoresistance, Stemness, and EMT Phenotype of Triple-Negative Breast Cancer Cells by egulating the Warburg Effect via c-Myc Deubiquitination

The Molecular Mechanisms of Regulation on USP2's Alternative Splicing and the Significance of Its Products.

USP18 promotes colon adenocarcinoma progression via targeting the ERK-MNK signaling pathway

USP42 drives nuclear speckle mRNA splicing via directing dynamic phase separation to promote tumorigenesis

Usp1-Wdr48 Deubiquitinase Complex Enhances Tgf-Beta Induced Epithelial-Mesenchymal Transition Of Tnbc Cells Via Stabilizing Tak1

USP19 Enhances MMP2/MMP9-Mediated Tumorigenesis in Gastric Cancer